{"id":"W1674196795","doi":"10.1016/s1473-3099(15)00152-8","title":"Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Infectious Diseases","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":204,"is_retracted":false,"has_abstract":false,"ca_institutions":"Maple Leaf Medical Clinic","funders":"Janssen Research and Development; ViiV Healthcare","keywords":"Rilpivirine; Efavirenz; Emtricitabine; Regimen; Medicine; Dolutegravir; Nucleoside Reverse Transcriptase Inhibitor; Internal medicine; Raltegravir; Reverse-transcriptase inhibitor; Pharmacology; Viral load; Virology; Human immunodeficiency virus (HIV); Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004724017,0.0006570139,0.00114453,0.0004580253,0.0002449226,0.0001177093,0.0001225031,0.0001581743,0.00004170561],"category_scores_gemma":[0.0001569967,0.0004080364,0.000228073,0.001059027,0.0002846913,0.0005701829,0.0000378631,0.0005983711,0.00005829168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001029602,"about_ca_system_score_gemma":0.0008326743,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002165498,"about_ca_topic_score_gemma":0.001252688,"domain_scores_codex":[0.9968618,0.000400738,0.0005972965,0.0007073217,0.0006995726,0.0007332368],"domain_scores_gemma":[0.9983343,0.0001378144,0.0002949078,0.0006097165,0.0001914895,0.0004317671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6856971,0.002406686,0.2907397,0.0002887204,0.0007325367,0.001588137,0.007485885,0.001082778,0.0001564584,0.00002157647,0.003051442,0.006748923],"study_design_scores_gemma":[0.9433708,0.004476647,0.03904147,0.002285376,0.002371223,0.0004187739,0.00174303,0.000955248,0.0004158323,0.0000711883,0.00375625,0.001094117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924901,0.0005131249,0.000390269,0.0008795336,0.0004813598,0.004005236,0.0001341791,0.0004164054,0.0006898674],"genre_scores_gemma":[0.9960639,0.0002172702,0.0001354601,0.00035563,0.001076612,0.00112397,0.0002838132,0.0000957099,0.00064767],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2576737,"threshold_uncertainty_score":0.9998372,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01747817052545608,"score_gpt":0.2684220902275357,"score_spread":0.2509439197020796,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}